TickerFacts.

Company research / PRGO

Perrigo Co PLC (PRGO)

Build a valuation ↗↓ Download CSV

SEC name PERRIGO Co plc · CIK 0001585364 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Perrigo Co PLC reported revenue of $4.25B. Revenue fell 2.8% from the prior annual period. Over the twelve months to 2026-06-27, revenue was $4.14B.

Key ratios (year ended 2025-12-31)

35.1%
Gross margin
-26.4%
Operating margin
-33.5%
Net margin
-48.6%
Return on year-end equity
-2.8%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-15

Headquarters locality: Ireland · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-27 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-27		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.14B$4.25B$4.37B$4.66B$4.45B$4.14B$4.09B$3.87B$4.73B$4.95B$5.28B
Cost of Revenue$2.77B$2.76B$2.83B$2.98B$3.00B$2.72B$2.59B$2.44B$2.90B$2.97B$3.23B
Gross Profit$1.38B$1.49B$1.54B$1.68B$1.46B$1.42B$1.49B$1.43B$1.83B$1.98B$2.05B
R&D Expense$95.10M$95.40M$112.20M$122.50M$123.10M$122.00M$121.70M$119.20M$218.60M$167.70M$184.00M
Operating Income-$1.56B-$1.12B$112.90M$151.90M$78.90M$410.40M$265.20M$174.70M$236.50M$598.20M-$2.00B
Depreciation & Amortization$350.40M$337.50M$325.90M$359.50M$338.60M$312.20M$384.80M$396.50M$423.60M$444.80M$457.00M
EBITDA-$1.21B-$784.70M$438.80M$511.40M$417.50M$722.60M$650.00M$571.20M$660.10M$1.04B-$1.54B
Net Income-$1.73B-$1.43B-$171.80M-$12.70M-$140.60M-$68.90M-$162.60M$146.10M$131.00M$119.60M-$4.01B
EPS (Diluted)n/a-$10.29-$1.25-$0.09-$1.04-$0.52-$1.19$1.07$0.95$0.84-$28.01
Total Assets$7.61B$8.54B$9.65B$10.81B$11.02B$10.43B$11.49B$11.30B$10.98B$11.63B$13.87B
Total Liabilities$5.09B$5.60B$5.33B$6.04B$6.18B$5.27B$5.83B$5.50B$5.32B$5.46B$7.91B
Shareholders' Equity$2.52B$2.94B$4.32B$4.77B$4.84B$5.15B$5.66B$5.80B$5.67B$6.17B$5.96B
Cash & Equivalentsn/an/an/an/a$600.70M$1.86B$631.50M$354.30M$551.10M$678.70M$622.30M
Operating Cash Flow$196.10M$238.50M$362.90M$405.50M$307.30M$156.30M$636.20M$387.80M$593.00M$698.90M$654.90M
Capital Expenditures$76.80M$93.40M$118.30M$101.70M$96.40M$152.10M$170.40M$137.70M$102.60M$88.60M$106.20M
Free Cash Flow$119.30M$145.10M$244.60M$303.80M$210.90M$4.20M$465.80M$250.10M$490.40M$610.30M$548.70M
Share Repurchasesn/an/an/an/a$0$0$164.20M$0$400.00M$191.50M$0
Dividends Paid$159.90M$159.30M$152.50M$149.70M$142.40M$129.60M$123.90M$112.40M$104.90M$91.10M$83.20M
Shares Outstanding138.70M137.60M136.50M135.50M134.70Mn/an/an/an/an/an/a
Dividends Per Sharen/a$1.16$1.10$1.09$1.04$0.96$0.90$0.82$0.76$0.64$0.58
Weighted Average Diluted Sharesn/a138.50M137.40M135.30M134.50M133.60M137.20M136.50M138.30M142.60M143.30M
EPS (Basic)n/a-$10.29-$1.25-$0.09-$1.04-$0.52-$1.20$1.07$0.95$0.84-$28.01

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView